Pamela Stearns, MD
Internal Medicine · Pembroke Pines, FLNPI 1376581801
Payments from drug & device makers
Across 315 payments — averaging $447.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$91K
- Novartis$34K
- Kowa Research Institute, Inc.$11K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$584
- Novo Nordisk$476
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,285100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $90,519 |
| Novartis | 7 | $34,262 |
| Kowa Research Institute, Inc. | 7 | $11,254 |
| Boehringer Ingelheim | 42 | $1,028 |
| Lilly USA, LLC | 38 | $584 |
| Novo Nordisk | 23 | $476 |
| Amarin Pharma, Inc. | 33 | $453 |
| Amgen(2 entities) | 20 | $359 |
| GSK | 18 | $345 |
| AstraZeneca | 16 | $317 |
| Pfizer | 14 | $312 |
| Teva Pharmaceuticals USA, Inc. | 6 | $154 |
| Exact Sciences | 5 | $112 |
| Merck | 5 | $107 |
| Gilead | 5 | $96 |
| Mayne Pharma Commercial LLC | 1 | $90 |
| Bayer | 3 | $67 |
| Ironwood Pharmaceuticals, Inc | 2 | $39 |
| Avion Pharmaceuticals | 3 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Insightec,inc | 1 | $29 |
| Biohaven Pharmaceuticals, Inc. | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Pharming Healthcare, Inc. | 1 | $26 |
| Abbott | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| CMP Pharma, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Agile Therapeutics, Inc. | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Lupin Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$141,010 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 127 | $143,665 |
| EliquisApixaban | 65 | $60,415 |
| OzempicSemaglutide | 28 | $37,345 |
| VascepaIcosapent Ethyl | 36 | $26,599 |
| ProliaDenosumab | 15 | $26,274 |
| JanuviaSitagliptin Phosphate | 20 | $21,347 |
| XareltoRivaroxaban | 13 | $20,188 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $19,102 |
| FarxigaDapagliflozin Propanediol | 24 | $18,648 |
| RybelsusSemaglutide | 16 | $16,896 |
| LinzessLinaclotide | 12 | $13,311 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $8,992 |
| Repatha SyringeEvolocumab | 12 | $6,771 |
| Atorvastatin Calcium | 695 | $5,079 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $3,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $1,028 | $143,665127 claims |
| PfizerEliquis | $312 | $60,41565 claims |
| Novo NordiskOzempic, Rybelsus | $476 | $54,24144 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $345 | $28,09439 claims |
| AmgenProlia | $359 | $26,27415 claims |
| MerckJanuvia | $107 | $21,34720 claims |
| Johnson & JohnsonXarelto | $18 | $20,18813 claims |
| AstraZenecaFarxiga | $317 | $18,64824 claims |
| AbbVieLinzess, Synthroid | $90,519 | $15,43337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Pembroke Pines
- Jaynier MoyaPembroke Pines$45.4M
- Yanely Pineiro PueblaPembroke Pines$12.4M
- Armando de FeriaPembroke Pines$11.8M
- Maria BermudezPembroke Pines$10.2M
- Robert PerryPembroke Pines$9.2M
- Ernesto FuentesPembroke Pines$9M
- Giralt Yanez RamosPembroke Pines$5.5M
- Kenneth BlazePembroke Pines$4.3M
- Reynold Duarte MartinezPembroke Pines$4.1M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.